When a company such as THRX splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the THRX split history from start to finish, an original position size of 1000 shares would have turned into 1241 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into THRX shares, starting with a $10,000 purchase of THRX, presented on a split-history-adjusted basis factoring in the complete THRX split history.

About THRX

Theseus Pharmaceuticals is engaged in the discovery, development and commercialization of targeted therapies for cancer patients. Co.'s development programs are designed to address drug resistance mutations in key driver oncogenes. Co.'s product candidate, THE-630, is a pan-variant inhibitor of all main classes of activating and resistance mutations of the KIT kinase for the treatment of gastrointestinal stromal tumours. Co.'s second program is focused on inhibitors of epidermal growth factor receptor (EGFR), that are active against C797S, the common EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. According to our THRX split history records, THRX has had 1 split.

THRX Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved